Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle dise…
$18.07+4.09%
报价 2026-11-06
市值
$3.37B
EV
$2.17B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -32.5%
$14.25$26.78
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| DYNDyne Therapeutics, Inc. | $3.37B | +4.1% | +42.9% | 0% | – | – | – | |
| CGONCG Oncology, Inc. Common stock | $6.74B | +17.3% | +378.6% | -102.2% | – | – | – | |
| MIRMMirum Pharmaceuticals, Inc. | $6.09B | +0.2% | +30.9% | 81.7% | – | – | – | |
| XENEXenon Pharmaceuticals Inc. | $3.79B | +4.0% | – | 0% | – | – | – | |
| CELCCelcuity Inc. | $3.27B | +4.3% | +4666.7% | 0% | – | – | – | |
| TLXTelix Pharmaceuticals Limited | $3.17B | +2.2% | – | 50.8% | – | 129.6x | – | |
| RAREUltragenyx Pharmaceutical Inc. | $1.52B | -0.9% | +11.6% | 83.1% | – | – | – | |
| AAPGASCENTAGE PHARMA GROUP INTERNATIONAL | $1.43B | +2.0% | – | 81.6% | – | – | – | |
| 同行中位数 | – | – | +204.7% | 50.8% | – | 129.6x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。